

# Interleukin 1 - Pipeline Review, H1 2020

<https://marketpublishers.com/r/I59A7192BF97EN.html>

Date: January 2020

Pages: 137

Price: US\$ 3,500.00 (Single User License)

ID: I59A7192BF97EN

## Abstracts

Interleukin 1 - Pipeline Review, H1 2020

### SUMMARY

Interleukin 1 (IL1) pipeline Target constitutes close to 24 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the universities/institutes. The latest report Interleukin 1 (IL1) - Pipeline Review, H1 2020, outlays comprehensive information on the Interleukin 1 (IL1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Interleukin 1 (IL1) - Interleukin-1 is a cytokine which plays an important role regulation of immune and inflammatory responses. It helps leukocytes pass through blood vessel walls to sites of infection and causes fever by affecting areas of the brain that control body temperature. There are two forms of interleukin-1, alpha and beta. IL-1 stimulates thymocyte proliferation by inducing IL-2 release, B-cell maturation and proliferation, and fibroblast growth factor activity. The molecules developed by companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 6, 2, 10 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Immunology, Oncology, Cardiovascular, Gastrointestinal, Musculoskeletal Disorders, Dermatology, Metabolic Disorders, Genetic Disorders, Central Nervous System, Ear Nose Throat Disorders, Genito Urinary System And Sex Hormones, Hematological Disorders and Respiratory which include indications Gouty Arthritis (Gout), Non-Small Cell Lung Cancer, Acne Vulgaris, Atopic Dermatitis (Atopic Eczema), Autoimmune Disorders, Behcet Disease, Colorectal Cancer, Epidermolysis Bullosa, Esophageal Cancer, Familial Mediterranean Fever, Inflammation, Metastatic Colorectal Cancer, Metastatic Melanoma, Muckle-Wells Syndrome, Ovarian Cancer, Prostate Cancer,

Renal Cell Carcinoma, Rheumatoid Arthritis, Triple-Negative Breast Cancer (TNBC), Type 2 Diabetes, Alcoholic Hepatitis, Allergic Rhinitis, Arterial Thrombosis, Atherosclerosis, Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Brain Cancer, Cancer Anorexia-Cachexia Syndrome, Cancer Pain, Cardiovascular Risk Factors, Cervical Cancer, Cholangitis, Crohn's Disease (Regional Enteritis), Diffuse Large B-Cell Lymphoma, Endometrial Cancer, Fallopian Tube Cancer, Familial Cold Autoinflammatory Syndrome (Familial Cold Urticaria), Follicular Lymphoma, Gastric Cancer, Glioblastoma Multiforme (GBM), Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hearing Disorders, Hidradenitis Suppurativa, Inflammatory Bowel Disease, Inflammatory Pain, Kidney Cancer (Renal Cell Cancer), Kidney Fibrosis, Limited/Distal Colitis, Liver Fibrosis, Lymphoma, Metastatic Breast Cancer, Metastatic Ovarian Cancer, Metastatic Prostate Cancer, Metastatic Renal Cell Carcinoma, Multiple Myeloma (Kahler Disease), Myocardial Infarction, Neonatal Onset Multisystem Inflammatory Disease, Neuropathic Pain (Neuralgia), Osteoarthritis, Osteosarcoma, Pancreatic Cancer, Pericarditis, Plaque Psoriasis (Psoriasis Vulgaris), Psoriasis, Pyoderma Gangrenosum, Recurrent Glioblastoma Multiforme (GBM), Restenosis, Sarcoidosis, Schnitzler Syndrome, Sickle Cell Disease, Soft Tissue Sarcoma, Squamous Non-Small Cell Lung Cancer, Systemic Juvenile Rheumatoid Arthritis, Systemic Sclerosis (Scleroderma) and Transitional Cell Cancer (Urothelial Cell Cancer).

Furthermore, this report also reviews key players involved in Interleukin 1 (IL1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Interleukin 1 (IL1)

The report reviews Interleukin 1 (IL1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Interleukin 1 (IL1) targeted therapeutics and enlists all their major and minor projects

The report assesses Interleukin 1 (IL1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Interleukin 1 (IL1) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Interleukin 1 (IL1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's

most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Interleukin 1 (IL1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Interleukin 1 (IL1) - Overview

Interleukin 1 (IL1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Interleukin 1 (IL1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Interleukin 1 (IL1) - Companies Involved in Therapeutics Development

3SBio Inc

Bioiberica SAU

Devonian Health Group Inc

Johnson & Johnson

Komipharm International Co Ltd

Link Health Group

Mabpharm Ltd

Moderna Therapeutics Inc

Novartis AG

Omnitura Therapeutics Inc

Opsona Therapeutics Ltd

Peptinov SAS

R Pharm

Regeneron Pharmaceuticals Inc

Spherium Biomed SL

Swedish Orphan Biovitrum AB

Therapicon Srl

TWi Biotechnology Inc

XBiotech Inc

Interleukin 1 (IL1) - Drug Profiles

AC-203 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bermekimab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Interleukin 1 (IL1) - Dormant Products

Interleukin 1 (IL1) - Discontinued Products

Interleukin 1 (IL1) - Product Development Milestones

Featured News & Press Releases

Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2020  
Number of Products under Development by Therapy Areas, H1 2020  
Number of Products under Development by Indications, H1 2020  
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020  
Number of Products under Development by Indications, H1 2020 (Contd..2), H1 2020  
Number of Products under Development by Indications, H1 2020 (Contd..3), H1 2020  
Number of Products under Development by Companies, H1 2020  
Products under Development by Companies, H1 2020  
Products under Development by Companies, H1 2020 (Contd..1), H1 2020  
Products under Development by Companies, H1 2020 (Contd..2), H1 2020  
Products under Development by Companies, H1 2020 (Contd..3), H1 2020  
Products under Development by Companies, H1 2020 (Contd..4), H1 2020  
Products under Development by Companies, H1 2020 (Contd..5), H1 2020  
Number of Products under Investigation by Universities/Institutes, H1 2020  
Products under Investigation by Universities/Institutes, H1 2020  
Number of Products by Stage and Mechanism of Actions, H1 2020  
Number of Products by Stage and Route of Administration, H1 2020  
Number of Products by Stage and Molecule Type, H1 2020  
Pipeline by 3SBio Inc, H1 2020  
Pipeline by Bioiberica SAU, H1 2020  
Pipeline by Devonian Health Group Inc, H1 2020  
Pipeline by Johnson & Johnson, H1 2020  
Pipeline by Komipharm International Co Ltd, H1 2020  
Pipeline by Link Health Group, H1 2020  
Pipeline by Mabpharm Ltd, H1 2020  
Pipeline by Moderna Therapeutics Inc, H1 2020  
Pipeline by Novartis AG, H1 2020  
Pipeline by Omnitura Therapeutics Inc, H1 2020  
Pipeline by Opsona Therapeutics Ltd, H1 2020  
Pipeline by Peptinov SAS, H1 2020  
Pipeline by R Pharm, H1 2020  
Pipeline by Regeneron Pharmaceuticals Inc, H1 2020  
Pipeline by Spherium Biomed SL, H1 2020  
Pipeline by Swedish Orphan Biovitrum AB, H1 2020  
Pipeline by Therapicon Srl, H1 2020

Pipeline by TWi Biotechnology Inc, H1 2020

Pipeline by XBiotech Inc, H1 2020

Dormant Products, H1 2020

Dormant Products, H1 2020 (Contd..1), H1 2020

Dormant Products, H1 2020 (Contd..2), H1 2020

Dormant Products, H1 2020 (Contd..3), H1 2020

Dormant Products, H1 2020 (Contd..4), H1 2020

Dormant Products, H1 2020 (Contd..5), H1 2020

Discontinued Products, H1 2020

Discontinued Products, H1 2020 (Contd..1), H1 2020

Discontinued Products, H1 2020 (Contd..2), H1 2020



## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2020  
Number of Products under Development by Therapy Areas, H1 2020  
Number of Products under Development by Top 10 Indications, H1 2020  
Number of Products by Mechanism of Actions, H1 2020  
Number of Products by Stage and Mechanism of Actions, H1 2020  
Number of Products by Routes of Administration, H1 2020  
Number of Products by Stage and Routes of Administration, H1 2020  
Number of Products by Molecule Types, H1 2020  
Number of Products by Stage and Molecule Types, H1 2020

### COMPANIES MENTIONED

3SBio Inc  
Bioiberica SAU  
Devonian Health Group Inc  
Johnson & Johnson  
Komipharm International Co Ltd  
Link Health Group  
Mabpharm Ltd  
Moderna Therapeutics Inc  
Novartis AG  
Omnitura Therapeutics Inc  
Opsona Therapeutics Ltd  
Peptinov SAS  
R Pharm  
Regeneron Pharmaceuticals Inc  
Spherium Biomed SL  
Swedish Orphan Biovitrum AB  
Therapicon Srl  
TWi Biotechnology Inc  
XBiotech Inc

## I would like to order

Product name: Interleukin 1 - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/I59A7192BF97EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/I59A7192BF97EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970